Can the dose of Olaparib be reduced?

Patients with BRCA1/-mutated, platinum-sensitive, recurrent ovarian cancer who required a reduction or interruption of olaparib (Olaparib) treatment during the first 12 weeks of treatment had no worse survival outcomes than patients who received the recommended dose, according to auxiliary findings from the SOLO2 study. These data suggest that patients who require a change in their PARP inhibitor therapy due to adverse events (AEs) will not be negatively affected.

Relative dose intensity (RDI) represents the dose administered during the first 12 weeks of treatment compared with the recommended standard dose (30 mg twice daily). The researchers classified participants as having an RDA greater than 98%, an RDI between 90% and 98%, and an RDI less than 90%. After 12 weeks of olaparib treatment, the average 12-week RDI was 91.4%. In addition, after 12 weeks of olaparib treatment, the median overall survival (OS) was 49.7 months in the greater than 98% group, 49.5% in the 90% to 98% group, and 54.1 months in the less than 90% group. Median progression-free survival (PFS) was 14.2 months, 49.5 months, and 54.1 months, respectively. In addition, patients who presented with baseline performance status of any nausea, or weighed 70 kg or less.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.